Genentech Study Backs Submission of New Herceptin/Pertuzumab Combo in HER2 Metastatic Breast Cancer
August 10, 2011
Genentech Study Backs Submission of New Herceptin/Pertuzumab Combo in HER2 Metastatic Breast Cancer
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Approves Dako Assays as CDx for Genentech Breast Cancer Drug
March 5, 2013 / GenomeWeb Daily News - Genentech Planning Regulatory Filing This Year for New Personalized Rx for Advanced Breast Cancer
June 6, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Siemens Inks Companion Dx Partnerships; FDA Accepts Roche's Pertuzumab BLA
February 8, 2012 / Pharmacogenomics Reporter - Ventana's Growing Companion Dx Focus Mirrors Parent Roche's Investment in Personalized Rx
January 18, 2012 / Pharmacogenomics Reporter - San Antonio Breast Cancer Symposium Presentations Highlight Personalized Cancer Treatment
December 14, 2011 / Pharmacogenomics Reporter